We are researching the combination of capivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer who have not responded to standard treatments. The study aims to evaluate treatment effectiveness and safety in real-world clinical practice.
Health conditions and diseases that the clinical trial is designed to study and treat.
Advanced breast cancer is a stage of breast cancer where the disease has spread beyond the breast and nearby lymph nodes. In HR+ / HER2- cases, the cancer cells grow in response to hormones but do not have excess HER2 protein, influencing treatment options.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.